GlycoMimetics Inc (GLYC)
0.3994
0.00 (0.00%)
USD |
NASDAQ |
Nov 14, 16:00
0.3994
0.00 (0.00%)
After-Hours: 05:03
GlycoMimetics Cash and Short Term Investments (Quarterly): 22.39M for June 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 22.39M |
| March 31, 2024 | 31.28M |
| December 31, 2023 | 41.79M |
| September 30, 2023 | 49.41M |
| June 30, 2023 | 58.04M |
| March 31, 2023 | 65.00M |
| December 31, 2022 | 47.87M |
| September 30, 2022 | 51.62M |
| June 30, 2022 | 60.24M |
| March 31, 2022 | 76.52M |
| December 31, 2021 | 90.25M |
| September 30, 2021 | 101.92M |
| June 30, 2021 | 118.85M |
| March 31, 2021 | 132.47M |
| December 31, 2020 | 137.04M |
| September 30, 2020 | 142.87M |
| June 30, 2020 | 149.84M |
| March 31, 2020 | 154.82M |
| December 31, 2019 | 158.20M |
| September 30, 2019 | 170.89M |
| June 30, 2019 | 184.17M |
| March 31, 2019 | 195.56M |
| December 31, 2018 | 209.92M |
| Date | Value |
|---|---|
| September 30, 2018 | 219.83M |
| June 30, 2018 | 229.43M |
| March 31, 2018 | 242.63M |
| December 31, 2017 | 123.92M |
| September 30, 2017 | 112.87M |
| June 30, 2017 | 119.15M |
| March 31, 2017 | 34.59M |
| December 31, 2016 | 40.04M |
| September 30, 2016 | 45.28M |
| June 30, 2016 | 53.09M |
| March 31, 2016 | 38.83M |
| December 31, 2015 | 46.80M |
| September 30, 2015 | 53.76M |
| June 30, 2015 | 40.23M |
| March 31, 2015 | 46.57M |
| December 31, 2014 | 55.20M |
| September 30, 2014 | 61.36M |
| June 30, 2014 | 66.22M |
| March 31, 2014 | 56.97M |
| December 31, 2013 | 2.311M |
| September 30, 2013 | 7.690M |
| June 30, 2013 | 10.78M |
| December 31, 2012 | 17.37M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
22.39M
Minimum
Jun 2024
158.20M
Maximum
Dec 2019
88.97M
Average
76.52M
Median
Mar 2022
Cash and Short Term Investments (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 930.44M |
| Arbutus Biopharma Corp | 127.79M |
| Revance Therapeutics Inc | 184.08M |
| FibroGen Inc | 140.71M |
| Cidara Therapeutics Inc | 127.39M |